Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» obesity
obesity
Obesity: Six trials to watch over the next 12 months
Clinical Trials Arena
Fri, 06/30/23 - 11:45 am
obesity
clinical trials
Novo Nordisk
Altimmune
Innovent Biologics
Pfizer
Shionogi
Tonix
semaglutide
oxytocin
permvidutide
mazdutide
danuglipron
ADA 2023 – Lilly unveils its triple threat
EP Vantage
Wed, 06/28/23 - 09:57 am
Eli Lilly
Novo Nordisk
retatrutide
Wegovy
Mounjaro
obesity
clinical trials
Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle
Fierce Biotech
Mon, 06/26/23 - 10:00 am
Eli Lilly
obesity
orforglipron
Pfizer
Novo Nordisk
Mounjaro
Pfizer, citing safety concerns, scraps one of two obesity pill hopefuls
BioPharma Dive
Mon, 06/26/23 - 09:57 am
Pfizer
obesity
lotiglipron
danuglipron
Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect
Fierce Biotech
Sun, 06/25/23 - 09:46 pm
Boehringer Ingelheim
obesity
clinical trials
Zealand Pharma
survodutide
Novo Nordisk says EMA raised safety signal on drugs including semaglutide
Yahoo/Reuters
Thu, 06/22/23 - 10:21 am
Novo Nordisk
EMA
semaglutide
Ozempic
Wegovy
thyroid cancer
obesity
diabetes
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
EP Vantage
Wed, 06/21/23 - 10:38 am
ADA
Eli Lilly
Pfizer
diabetes
obesity
orforglipron
danuglipron
lotiglipron
Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report
Fierce Pharma
Mon, 06/19/23 - 10:29 am
Eli Lilly
Novo Nordisk
Mounjaro
semaglutide
diabetes
obesity
This Biotech Is Developing The Next Ozempic
Motley Fool
Fri, 06/16/23 - 10:11 am
Structure Therapeutics
diabetes
obesity
Ozempic
Eli Lilly’s Mounjaro likely to become ‘leading therapy’ for obesity and type 2 diabetes
Biopharma Reporter
Thu, 06/15/23 - 10:06 am
Eli Lilly
Mounjaro
obesity
type 2 diabetes
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Biopharma Reporter
Wed, 05/31/23 - 11:08 am
obesity
weight loss
Novo Nordisk
Eli Lilly
Pfizer
Amgen
Lilly steps up its oral obesity push
EP Vantage
Thu, 05/25/23 - 08:45 pm
Eli Lilly
obesity
GLP-1 agonist
orforglipron
Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Fierce Biotech
Fri, 05/12/23 - 11:41 am
Innovent
Eli Lilly
obesity
mazdutide
clinical trials
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
BioSpace
Wed, 05/10/23 - 10:21 am
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Stat
Tue, 05/9/23 - 10:33 am
side effects
Ozempic
Wegovy
Mounjaro
Novo Nordisk
Eli Lilly
obesity
Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy
Fierce Pharma
Thu, 05/4/23 - 09:05 pm
Novo Nordisk
Wegovy
obesity
Quitting Lilly's obesity drug tirzepatide may be difficult for many patients, exec says
Fierce Pharma
Thu, 04/27/23 - 10:48 pm
Eli Lilly
obesity
tirzepatide
patients
Lilly drug Mounjaro succeeds in second weight loss study
BioPharma Dive
Thu, 04/27/23 - 11:43 am
Eli Lilly
obesity
Mounjaro
clinical trials
In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy
Fierce Pharma
Mon, 04/24/23 - 10:20 am
Eli Lilly
clinical trials
obesity
Mounjaro
Novo Nordisk
Wegovy
Novo’s latest deal targets cell therapy for diabetes, obesity
BioPharma Dive
Thu, 04/13/23 - 12:02 pm
Novo Nordisk
cell therapy
diabetes
obesity
Aspect Biosystems
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »